Loading...
XNASFATE
Market cap183mUSD
Dec 27, Last price  
1.61USD
1D
-0.62%
1Q
-54.90%
Jan 2017
-35.86%
IPO
-76.83%
Name

Fate Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:FATE chart
P/E
—
P/S
2.89
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.86%
Rev. gr., 5y
68.05%
Revenues
64m
-34.03%
1,170,0002,670,000971,00002,431,0004,402,0004,106,0004,740,00010,680,00031,434,00055,846,00096,300,00063,533,000
Net income
-161m
L-36.90%
-13,427,000-14,239,000-20,894,000-25,883,000-29,992,000-33,462,000-42,952,000-66,598,000-97,708,000-170,300,000-206,301,000-255,056,000-160,928,000
CFO
-132m
L-46.71%
-12,145,000-13,274,000-15,373,000-22,419,000-18,397,000-29,823,000-36,905,000-38,650,000-83,175,000-39,229,000-162,870,000-248,208,000-132,263,000
Earnings
Feb 24, 2025

Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
URL
https://fatetherapeutics.com/
IPO date
Oct 01, 2013
Employees
551
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
63,533
-34.03%
96,300
72.44%
55,846
77.66%
Cost of revenue
413,740
418,444
278,690
Unusual Expense (Income)
NOPBT
(350,207)
(322,144)
(222,844)
NOPBT Margin
Operating Taxes
(26,665)
(5,850)
Tax Rate
NOPAT
(350,207)
(295,479)
(216,994)
Net income
(160,928)
-36.90%
(255,056)
23.63%
(206,301)
21.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
85
9,207
453,129
BB yield
-0.02%
-0.94%
-8.17%
Debt
Debt current
12,352
5,628
5,577
Long-term debt
200,896
213,048
224,059
Deferred revenue
27,124
Other long-term liabilities
1,346
3,861
800
Net debt
(102,907)
(222,493)
(486,938)
Cash flow
Cash from operating activities
(132,263)
(248,208)
(162,870)
CAPEX
(6,153)
(35,566)
(50,704)
Cash from investing activities
112,665
166,751
(324,023)
Cash from financing activities
85
9,207
453,129
FCF
(442,649)
(290,828)
(220,630)
Balance
Cash
315,175
436,227
615,910
Long term investments
980
4,942
100,664
Excess cash
312,978
436,354
713,782
Stockholders' equity
(1,211,615)
(1,052,558)
(769,746)
Invested Capital
1,691,090
1,649,696
1,591,326
ROIC
ROCE
EV
Common stock shares outstanding
98,411
96,826
94,747
Price
3.74
-62.93%
10.09
-82.76%
58.51
-35.65%
Market cap
368,058
-62.33%
976,975
-82.38%
5,543,665
-26.00%
EV
265,154
754,485
5,056,730
EBITDA
(331,925)
(308,386)
(216,994)
EV/EBITDA
Interest
5,842
Interest/NOPBT